- GR-MD-02 was safe and well tolerated in patients
- Galectin Therapeutics to host webcast, April 1, 8:30 a.m. EDT to discuss first cohort findings
- Second cohort of Phase 1 trial to begin enrollment in April
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
Galectin Therapeutics (GALT) plummeted Tuesday after the company reported poor results in an early-stage trial of its experimental drug for treatment of a fatty liver disease.